High-dose Zevalin with stem cell transplant may benefit NHL patients

10/21/2008 | RTT News

A study showed that 83% of patients with relapsed/refractory or high-risk aggressive non-Hodgkin's lymphoma were disease-free 30 months after receiving high-dose Zevalin and undergoing a tandem stem cell transplant. The findings add to evidence that "Zevalin at higher than FDA approved doses with a stem cell rescue may provide an added clinical benefit" when combined with standard chemotherapy, a company official said.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC